FK506 in the treatment of inflammatory skin disease: promises and perspectives.

Abstract

The immunosuppressive macrolide drug FK506 is currently gaining increasing importance in dermatopharmacology. Here, Gunter Michel and colleagues summarize the current state of research into the molecular mechanisms responsible for the functional modulation of cell types other than T cells, particularly epidermal cells, by this drug. 

Topics

Cite this paper

@article{Michel1996FK506IT, title={FK506 in the treatment of inflammatory skin disease: promises and perspectives.}, author={G. Michel and Lajos Kem{\'e}ny and Bernhard Homey and Thomas Ruzicka}, journal={Immunology today}, year={1996}, volume={17 3}, pages={106-8} }